Icyrab-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Rabeprazole 20mg, designed for the effective management of gastrointestinal disorders. Domperidone, a dopamine D2 receptor antagonist, primarily acts as a prokinetic agent, enhancing gastrointestinal motility and facilitating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing symptomatic relief in conditions associated with hyperacidity such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The combined action of Domperidone and Rabeprazole in Icyrab-DSR Capsule offers a synergistic therapeutic effect, addressing both motility disturbances and acid-related mucosal damage. This combination is particularly beneficial in patients experiencing dyspepsia with delayed gastric emptying and acid reflux. Icyrab-DSR Capsule should be administered under medical supervision, considering contraindications such as hypersensitivity to either component and caution in patients with cardiac arrhythmias or hepatic impairment. Adverse effects may include dry mouth, headache, abdominal cramps, and, rarely, extrapyramidal symptoms. Overall, Icyrab-DSR Capsule is an effective treatment option for managing complex upper gastrointestinal conditions requiring both prokinetic and acid-suppressive therapy.